TG Therapeutics down 11% following Q2 bottom line miss
· seekingalpha.com
TG Therapeutics stock drops after Q2 EPS miss despite surging Briumvi sales and raised 2026 revenue guidance. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...